Silver Book Fact

Donepezil, a cholinesterase inhibitor, has been found to slow progression of Alzheimer’s disease in its early stages, delaying the need for nursing home care by an average of 30 months.

Provenzano, George, Sandeep Duttagupta, Thomas McRae, et al. Delays in Nursing Home Placement for Patients with Alzheimer s Disease Associated with Donepezil May Have Care Cost Savings Implications. Value in Health. 2001; 4(2): 158. https://www.valueinhealthjournal.com/article/S1098-3015(11)71392-4/abstract

Reference

Title
Delays in Nursing Home Placement for Patients with Alzheimer s Disease Associated with Donepezil May Have Care Cost Savings Implications
Publication
Value in Health
Publication Date
2001
Authors
Provenzano, George, Sandeep Duttagupta, Thomas McRae, et al
Volume & Issue
Volume 4, Issue 2
Pages
158
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • “A treatment breakthrough that delayed the age of onset of Alzheimer’s disease by five years and began to show its effects in 2015 would decrease the total number of Americans…  
  • An Alzheimer’s disease treatment breakthrough that slowed its progression and began to show its effects in 2015, would reduce the Medicare costs for people with the disease by $20 billion…  
  • Studies by the National Center for Complementary and Alternative Medicine (NCCAM) at NIH are looking at the neuroprotective qualities of diets rich in B vitamins and antioxidant phytochemicals. These nutrients…  
  • Donepezil, a new Alzheimer’s medication, increased prescription costs to $1,000 per patient, however the overall health care costs decreased from $11,947 to $8,056.  
  • Impact of a 5-Year Delay in Onset by Stage of Disease, Americans Age 65 and Older with Alzheimer’s Disease, 2050